R&D

R&D is
the heart of our mission to develop global medicines for incurable diseases.

Pipeline for New Medicine

R&D_Pipeline

 US,   China )
R&D_Pipeline
Project code Indication Discovery Preclinical Phase1 Phase2 Phase3 Partners
Immunology HL036 (tanfanercept) Dry eye disease
(DED)
대웅제약  하버바이오메드
(China)
HL161 (batoclimab) Myasthenia gravis
(MG)
IMMUNOVANT  하버바이오메드
(US/EU) (China)
Thyroid eye disease
(TED)
IMMUNOVANT  하버바이오메드
(US/EU) (China)
Warm autoimmune
hemolytic anemia
(WAIHA)
IMMUNOVANT
(US/EU)
Neuromyelitis optica
(NMO)
하버바이오메드
(China)
Immune thrombocytopenia
(ITP)
하버바이오메드
(China)
HL189 (tanfanercept) Non-Infectious
uveitis(NIU)
Oncology HL186/HL187 Immuno-oncology 대웅제약